| pubmed-article:7440697 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7440697 | lifeskim:mentions | umls-concept:C0024399 | lld:lifeskim |
| pubmed-article:7440697 | lifeskim:mentions | umls-concept:C0014939 | lld:lifeskim |
| pubmed-article:7440697 | lifeskim:mentions | umls-concept:C0010096 | lld:lifeskim |
| pubmed-article:7440697 | lifeskim:mentions | umls-concept:C0599739 | lld:lifeskim |
| pubmed-article:7440697 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:7440697 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:7440697 | pubmed:dateCreated | 1981-2-19 | lld:pubmed |
| pubmed-article:7440697 | pubmed:abstractText | Sequential administration of estrogen (40 microgram depoestradiol cypionate and estradiol benzoate) on cycle days 18--20 and bromergocryptine (CB-154; 0.5 mg/kg, twice daily) on cycle days 20-22 induced luteolysis in seven of nine cynomolgus monkeys, significantly shortened menstrual cycles (23.5 +/- 0.7 days), and caused a significant decline in plasma progesterone levels during the period of CB-154 administration. Two treated monkeys did not have shortened menstrual cycles, although a luteolytic effect on plasma progesterone was evident. One monkey with a late ovulation (confirmed by endocrine parameters and laparoscopic observation) was treated with the same regimen in the early luteal phase; this also resulted in a decline in plasma progesterone and a shortened luteal phase (11 days). Treatment with the estrogen or the CB-154 component alone had no effect on menstrual cycle length or plasma progesterone levels. Similarly, treatment with CB-154 throughout the luteal phase had no effect on luteal function. An abbreviated treatment consisting of 1 day of estrogen and 1 day of CB-154 administration gave some indication of a luteolytic effect. None of these treatments produced detectable side effects. These studies have demonstrated a synergism of estrogen and CB-154 in the induction of luteolysis in cynomolgus monkeys. The present regimen, because of the effectiveness and apparent lack of side effects, deserves further investigation for possible clinical application. | lld:pubmed |
| pubmed-article:7440697 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7440697 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:7440697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7440697 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7440697 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:7440697 | pubmed:issn | 0021-972X | lld:pubmed |
| pubmed-article:7440697 | pubmed:author | pubmed-author:ShaikhA AAA | lld:pubmed |
| pubmed-article:7440697 | pubmed:author | pubmed-author:CastracaneV... | lld:pubmed |
| pubmed-article:7440697 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7440697 | pubmed:volume | 51 | lld:pubmed |
| pubmed-article:7440697 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7440697 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7440697 | pubmed:pagination | 1311-5 | lld:pubmed |
| pubmed-article:7440697 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:meshHeading | pubmed-meshheading:7440697-... | lld:pubmed |
| pubmed-article:7440697 | pubmed:year | 1980 | lld:pubmed |
| pubmed-article:7440697 | pubmed:articleTitle | Synergism of estrogen and bromergocryptine in the induction of luteolysis in cynomolgus monkeys (Macaca fascicularis). | lld:pubmed |
| pubmed-article:7440697 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7440697 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
